Updates are available Correction dated 2021-09-24
Click to view Correction: https://doi.org/10.1038/s43018-021-00277-7
-
Authors
Milone, Michael C.
Xu, Jie
Chen, Sai-Juan
Collins, McKensie A.
Zhou, Jianfeng
Powell, Daniel J. Jr http://orcid.org/0000-0002-5966-8908
Melenhorst, J. Joseph http://orcid.org/0000-0001-7677-537X
- License Information
-
More Information
Article History
Received: 28 February 2020
Accepted: 28 June 2021
First Online: 19 August 2021
Change Date: 24 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-021-00277-7
Competing interests
: J.J.M., D.J.P. Jr and M.C.M. are inventors on several patents issued and pending in the field of CAR T cell therapy for cancer, which are assigned to the University of Pennsylvania. Under the University of Pennsylvania’s policies, J.J.M., D.J.P. Jr and M.C.M. either currently, or may in the future, receive royalties from the licensing of these patent rights. M.C.M. is an inventor on issued and pending patents related to CAR technology, and receives royalties from the licensing of this IP. He is also a founder and equity holder in Cabaletta Bio. J.X., S.-J.C. and M.A.C. have no conflicts of interest. J.Z. receives research funding from and is chairman of the Medical and Scientific Advisory Board of IASO Biotherapeutics. D.J.P. Jr is or has provided consultation for Iovance Biotherapeutics, Bellicum Pharmaceuticals, Neon Therapeutics, and Tmunity Therapeutics, and holds patents in the areas of tumor-infiltrating lymphocytes and gene-engineered T cells. J.J.M. receives research funding from IASO Biotherapeutics, consult for Simcere of America, Shanghai Unicar Therapy, Johnson & Johnson, Poseida, and IASO Biotherapeutics, and is on the Medical and Scientific Advisory Board of IASO Biotherapeutics and Poseida Therapeutics. J.J.M. further holds patents related to CAR T cell manufacturing and biomarkers.
